Skip to main content

Septic Shock clinical trials at UCSF
3 in progress, 2 open to new patients

  • An Algorithm Driven Sepsis Prediction Biomarker

    open to eligible people ages 18 years and up

    A sepsis early warning predictive algorithm, InSight, has been developed and validated on a large, diverse patient cohort. In this prospective study, the ability of InSight to predict severe sepsis patients is investigated. Specifically, InSight is compared with a well established severe sepsis detector in the UCSF electronic health record (EHR).

    San Francisco, California

  • Crystalloid Liberal or Vasopressors Early Resuscitation in Sepsis

    open to eligible people ages 18 years and up

    Multicenter, prospective, phase 3 randomized non-blinded interventional trial of fluid treatment strategies in the first 24 hours for patients with sepsis-induced hypotension. The aim of the study is to determine the impact of a restrictive fluids strategy (vasopressors first followed by rescue fluids) as compared to a liberal fluid strategy (fluids first followed by rescue vasopressors) on 90-day in-hospital mortality in patients with sepsis-induced hypotension.

    Fresno, California and other locations

  • Stress Hydrocortisone In Pediatric Septic Shock

    Sorry, not yet accepting patients

    SHIPSS is a multi-institutional, prospective, controlled, randomized, double-blinded interventional trial that will examine the potential benefits and risks of adjunctive hydrocortisone prescribed for children with fluid and vasoactive-inotropic refractory septic shock. It is hypothesized that adjunctive hydrocortisone will significantly reduce the proportion of children with poor outcomes, defined as death or severely impaired health-related quality of life, as assessed at 28 days following admission to a pediatric intensive care unit for the sepsis event.

    Oakland, California and other locations